Table 1 Patient demographics
Characteristic | Low risk (n = 31) | High risk (n = 44) | Total (n = 75) |
|---|---|---|---|
Age at surgery | |||
 Median years (range) | 61 (45–76) | 64 (44–77) | 63 (44–77) |
PSA at diagnosis | |||
 Median No. (range) | 6.6 (4–16.7) | 10 (1.8–140) | 8.5 (1.8–140) |
PSA at day biobanked | |||
 Median No. (range) | 0.1 (0–1.7) | 0.1 (0–16.6) | 0.11 (0–16.6) |
No. Gleason score (%) | |||
 6 | 3 (10) | 0 | 3 (4) |
 7 | 28 (90) | 19 (43) | 47 (63) |
 8 | 0 | 9 (20) | 9 (12) |
 9 | 0 | 16 (36) | 16 (21) |
No. pathological tumour stage (%) | |||
 ≤ pT2 | 23 (74) | 3 (7) | 26 (35) |
 pT3a | 8 (26) | 22 (50) | 30 (40) |
 pT3b | 0 | 18 (41) | 18 (24) |
 pT4 | 0 | 1 (2) | 1 (1) |
No. margin status (%) | |||
 Positive | 11 (35) | 30 (68) | 41 (55) |
 Negative | 20 (65) | 14 (32) | 34 (45) |
No. salvage therapy (%) | |||
 Radiation | 23 (74) | 33 (75) | 56 (75) |
 Hormone | 16 (52) | 34 (77) | 50 (67) |